Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced on September 2, 2026, the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist and expert in spectroscopy will contribute his scientific knowledge in spectroscopy and materials research to support the company's research initiatives.
Uwe Perbandt, CEO of Viromed Medical AG, emphasized the strategic value of the appointment: "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Prof. Dr. Rubhausen currently heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the Institute's Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on advanced spectroscopic methods, including Raman spectroscopy and ellipsometry, which he applies to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH.
With over 180 publications and approximately 4,000 citations, Prof. Dr. Rubhausen has contributed to prestigious journals including Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Additionally, he develops AI-supported analysis workflows for complex, high-dimensional datasets, a skill set that could prove valuable in analyzing cold plasma interactions with biological materials.
Viromed Medical AG specializes in the development, manufacture, and distribution of medical products, with a focus on cold plasma technology through its wholly owned subsidiary, Viromed Medical GmbH. The company has been listed on the stock exchange since October 2022 and serves a broad customer base in the DACH region and beyond. The addition of Prof. Dr. Rubhausen to the Medical Advisory Board underscores Viromed's commitment to advancing cold plasma applications in medicine.
The appointment comes at a time when cold plasma technology is gaining attention for its potential in wound healing, infection control, and cancer treatment. Rubhausen's expertise in spectroscopy and materials science could help Viromed better understand the fundamental mechanisms of cold plasma interactions with biological tissues, potentially leading to more effective and safe medical devices.
For more information about Viromed Medical AG and its products, visit their official website at www.viromed-medical-ag.de. The original press release is available on NewMediaWire.
